Vivo Capital — 2016 Investments
3 investments dated 2016 · listed companies and verified rows first · show all
BiotechSanta Clara, US
Jeffrey Glenn(Director)David Cory(Executive Officer, Director)
BoardNina Kjellson(Director)inEd Engleman(Director)
Board seatEdgar G. Engleman· per SEC Form D · $3M raise · filed Apr 2016
Co-investorsPfizer Venture InvestmentsCanaan Partners
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardVictor Tong(Director)Thomas Grogan(Director)
Board seatYuh-geng Tsay· per SEC Form D · $23M raise · filed Sep 2016
Co-investorsLAVLilly Asia VenturesLilly Ventures
Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
BiotechMedical DevicesPalo Alto, US
Xiaoling Charlene Liao(Executive Officer, Director)
BoardGuo-Liang Yu(Director)Liqun Luo(Director)
Co-investorsNorthern Light Venture CapitalShangBay Capital LLC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.